3D Signatures makes final payment for CancerCare patent

3D Signatures Inc. (TSXV:DXD)has recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS on June 26, 2014. Quarterly cash payments made by 3DS to CCMB totaled $269,617.75 over a 24 month period. CCMB retains a 1.5% royalty on all gross revenues derived from the commercialization of the patent rights and related products.
“CCBM has been an excellent partner and we see a number of opportunities for further collaboration based on some very recent and productive discussions,” noted Jason Flowerday, CEO of 3DS. “The intellectual property acquired from CCMB is at the core of our proprietary TeloViewTM software platform, which, to-date, has successfully identified and correlated distinct 3D telomere signatures in 13 different cancers and Alzheimer’s disease. We believe that TeloViewTM is a valuable and disruptive technology that will lead to multiple commercial tests as well as collaborations with biopharma partners that share our commitment to personalized medicine.”
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at https://www.3dsignatures.com.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
This email was sent to you at clientpr@resourceinvestingnews.com by Stockwatch (www.stockwatch.com) as part of your package of Stockwatch services, and in accordance with your email preferences on file. You may unsubscribe at any time, or change your email preferences within Your Account settings at the Stockwatch website. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY. You may contact Stockwatch by email at webmaster@stockwatch.com, by phone at 1-800-268-6397 (1-604-687-1500), or by mail to Stockwatch, PO Box 10371, 700 West Georgia Street, Vancouver, BC, V7Y 1J6, Canada. “Stockwatch” is a registered trademark of Canjex Publishing Ltd. Copyright © 2017, Canjex Publishing Ltd. All rights reserved.